• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[肺结核患者内源性干扰素γ水平与肝毒性肝损伤风险之间的关系]

[Relationship between the endogenous interferon IFN-gamma level and risk of hepatotoxic liver damage in tuberculosis patients].

作者信息

Sukhanov D S, Okovityĭ S V, Demidik S N, Ivanov A K, Romantsov M G

出版信息

Eksp Klin Farmakol. 2012;75(6):40-3.

PMID:22891441
Abstract

Results of investigation in a group of 91 patients with infiltrative and disseminative forms of tuberculosis are presented. It is established that, at an initial level of IFN-gamma below 100 pg/ml, a higher frequency of development of the drug-induced liver injury takes place as manifested by increasing activity of the basic markers of cytolysis. Administration of the interferon inductor (cycloferon) favors positive clinical and laboratory dynamics of the tubercular process, increases the level of endogenous IFN-gamma (especially for an initial level below 100 pg/ml), and restricts the expression of drug-induced hepatotoxicity reactions.

摘要

本文介绍了对91例浸润性和播散性肺结核患者的调查结果。已确定,在初始干扰素-γ水平低于100 pg/ml时,药物性肝损伤的发生率更高,表现为细胞溶解基本标志物活性增加。给予干扰素诱导剂(环磷酰胺)有利于结核病程的积极临床和实验室动态变化,提高内源性干扰素-γ水平(尤其是初始水平低于100 pg/ml时),并限制药物性肝毒性反应的表达。

相似文献

1
[Relationship between the endogenous interferon IFN-gamma level and risk of hepatotoxic liver damage in tuberculosis patients].[肺结核患者内源性干扰素γ水平与肝毒性肝损伤风险之间的关系]
Eksp Klin Farmakol. 2012;75(6):40-3.
2
[Meglumine acridonacetate and complex therapy of patients with newly identified advanced pulmonary tuberculosis].[醋氮酰胺葡甲胺与新确诊的晚期肺结核患者的综合治疗]
Antibiot Khimioter. 2014;59(5-6):15-9.
3
[Cycloferon in the complex therapy of patients with widespread forms of pulmonary tuberculosis].
Eksp Klin Farmakol. 2012;75(5):17-20.
4
[Influence of therapy with interferon inducer on the parameters of quality of life in patients with pulmonary tuberculosis].
Lik Sprava. 2013 Mar(2):93-8.
5
[Value of some liver function tests routinely performed in early detection of damage to liver parenchyma in patients with pulmonary tuberculosis].[某些肝功能检查在肺结核患者肝实质损伤早期检测中的价值]
Gruzlica. 1971 Dec;39(12):1205-9.
6
[Characteristics of immune response to etiotropic and pathogenetic therapy in children with chronic hepatitis C].[慢性丙型肝炎患儿对病因导向性和致病性治疗的免疫反应特征]
Eksp Klin Farmakol. 2011;74(12):33-5.
7
Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: A randomized controlled trial.一种肝保护剂预防抗结核药物性肝损伤的随机对照试验。
J Gastroenterol Hepatol. 2016 Feb;31(2):409-16. doi: 10.1111/jgh.13070.
8
Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.埃塞俄比亚南部达罗地区结核病患者中抗结核药物所致肝毒性的发生率及相关危险因素:一项队列研究
Int J Mycobacteriol. 2016 Mar;5(1):14-20. doi: 10.1016/j.ijmyco.2015.10.002. Epub 2015 Oct 30.
9
[ASSESSMENT OF INDICATORS FOR INTERFERON SYSTEM IN PATIENTS WITH COMMON FORMS OF PULMONARY TUBERCULOSIS RECEIVING COMPLEX THERAPY WITH CYCLOFERON].
Eksp Klin Farmakol. 2015;78(6):15-8.
10
[Immunotropic and antihypoxant therapy of experimental drug-sensitive and drug-resistant tuberculosis].
Patol Fiziol Eksp Ter. 2013 Jan-Mar(1):65-9.